May 30, 2008 -- InSite Vision Incorporated (AMEX: ISV) of Alameda, CA has out-licensed to Essex Bio-Technology Limited the China rights for AzaSite® (azithromycin ophthalmic solution) 1%, an antiseptic eye drop. Essex will be responsible for securing SFDA approval of the product as a treatment for ocular bacterial infection. Essex is listed on the Growth Enterprise Market (GEM) of the Hong Kong Exchange (Stock Code: 8151). More details...
